Displaying drugs 1151 - 1175 of 1649 in total
INCB-057643
INCB-057643 is under investigation in clinical trial NCT02959437 (Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)).
Investigational
Matched Name: … INCB-057643 …
Matched Description: … INCB-057643 is under investigation in clinical trial NCT02959437 (Azacitidine Combined With Pembrolizumab …
Matched Description: … INCB-057643 is under investigation in clinical trial NCT02959437 (Azacitidine Combined With Pembrolizumab …
PF-07304814
PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects . PF-07304814, developed by Pfizer, was first identified during the...
Investigational
Matched Name: … PF-07304814 …
Matched Description: … Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its ... PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) ... PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was …
Matched Description: … Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its ... PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) ... PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was …
JCAR014
Investigational
PF-07799933
PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.
Investigational
Matched Name: … PF-07799933 …
Matched Description: … PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer. …
Matched Description: … PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer. …
PF-05230907
PF-05230907 is a recombinant activated Factor X variant.
Investigational
Matched Name: … PF-05230907 …
Matched Description: … PF-05230907 is a recombinant activated Factor X variant. …
Matched Description: … PF-05230907 is a recombinant activated Factor X variant. …
Protoporphyrin Ix Containing Co
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid ... 10,15-diethenyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-cobaltaoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
Verdoheme
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3,5,8,10,12,14,16,18(22),19,21(24)-decaen-22-ylium ... diethenyl-5,10,14,20-tetramethyl-7-oxa-2,22lambda5,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
AZD-5991
AZD-5991 is under investigation in clinical trial NCT03218683 (Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.).
Investigational
Matched Iupac: … 11,15}.0^{16,21}.0^{20,24}.0^{30,35}]octatriaconta-1(36),4(38),6,11,14,16,18,20,23,29(37),30(35),31,33 ... 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1^{4,7}.0^{ …
Staurosporine
An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
Experimental
Matched Iupac: … }.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one ... (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28 …
Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe)
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid ... ethenyl-10-ethyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
Zn(Ii)-(20-Oxo-Protoporphyrin Ix)
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid ... diethenyl-17-hydroxy-5,10,15,19-tetramethyl-2,22,23,25-tetraaza-1-zincaoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
MB07811
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
MB07133
Investigational
BI-K0376
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Investigational
MRx0518
Investigational
R048-8071
Experimental
MLN0415
MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these...
Investigational
PEP0101
PEP0101 is a nanocomplex consisting of elastin-like polypeptides and a small interfering RNA (siRNA) designed to down-regulate the expression of EVI1 oncogene in cancer cells.
Investigational
RGG0853
RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.
Investigational
Dimethyl Propionate Ester Heme
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoate ... methoxy-3-oxopropyl)-5,10,15,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
1,2,3-TRIHYDROXY-1,2,3,4-TETRAHYDROBENZO[A]PYRENE
Experimental
Matched Iupac: … (4R,5R,6R)-pentacyclo[10.6.2.0^{2,7}.0^{9,19}.0^{16,20}]icosa-1,7,9,11,13,15,17,19-octaene-4,5,6-triol …
Diacetyldeuteroheme
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid ... -hydroxyethenyl)-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
Lemzoparlimab
Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome).
Investigational
7-carboxy-5-hydroxy-12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole
Experimental
Matched Iupac: … 14-hydroxy-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4( …
Displaying drugs 1151 - 1175 of 1649 in total